Quarterly ResultMay 4, 2026, 07:31 AM
Twist Bioscience Q2 Revenue $110.7M, Raises FY26 Guidance
AI Summary
Twist Bioscience reported record fiscal second-quarter 2026 revenue of $110.7 million, a 19% increase year-over-year, marking its 13th consecutive quarter of growth. The company also improved its gross margin to 51.6% and raised its full fiscal year 2026 revenue guidance to $442-$447 million. Twist reiterated its expectation to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026, while also announcing new partnerships and product launches.
Key Highlights
- Record Q2 FY26 revenue reached $110.7 million, a 19% increase from $92.8 million in Q2 FY25.
- Gross margin improved to 51.6% in Q2 FY26, up from 49.6% in the prior year.
- Net loss for Q2 FY26 was $44.0 million, or $0.71 per share, compared to $39.3 million in Q2 FY25.
- Adjusted EBITDA for Q2 FY26 improved to $(13.3) million from $(14.8) million year-over-year.
- Raised full fiscal year 2026 revenue guidance to $442-$447 million, up from $435-$440 million.
- Reiterated expectation to achieve adjusted EBITDA breakeven in Q4 FY26.
- DNA Synthesis and Protein Solutions revenue grew 28% to $53.3 million.
- NGS Applications revenue grew 12% to $57.4 million.